Sharafi nejhad, Masoumeh

Simorgh Research Repository

3Lf ;Lr.: e **:rlq sL.l-- , ,,S,ii pgJc "t51"::;lc)y, .pl u,u.;.qt' *S-; o.rillc*U OL-L-*S-; d9-".c.r.5r a-7;c c.3Lrt c.4;'jl9-ro*l7 ot-1Lr.: a, or;f +'-1r," 'S;11 c..y; rf .-,lrk: ,, 1r1*; *c Si;l" .rJ! ,_L;'[rK\Ylf JL rc tt::.-,L-,L*: L;ol,.:L:-".1.r-!)t d-+ar;5" et-:r9L*.- .r;'Ll..r-_uJl 6U' aJl,o ;5c *;1";I U,,erH'1' tS'r'>l a-o';ss 'r;L';i,ly',ti), .r,K : c.o":i$'"la(oJII "rg.rj aa9"a:.ocd.YP 1Y12 Jy.-,{-r.r-----? trr e drti" -ta!l(Vernal keratoconjunctivitis) "rton d.-{J- pre : a.arLlr;.i :-c.s9.- rl ,rt$j i--at5 ,c J*;l 9 *.d? r,-;: ..r-rlf * F^ sl9, .f af "r-i! ,.s",.. ir*, -;c il .o- )l d;A^ ;1 1l -i-ro.crlc ;91*. gL ,_elf a5 c* 1 o.:L gYl ;Jr- .:9coj,^j o5.r-i.:9-o: a->\y Jt.j L"i, rLrL.r J-; e-* f :^ ot.i_;11 .-e.y-i,-S,:-:j-.-:-.$.l.; 4.JlL J_,1.1 .,- 7? 9 os;;.iliJl U"F) ;J ,SxS {y. C:; a : >;P t1 IrL:r**c .9911,: cr9- os-F ;s JJr: o*--rJsb I s;y o:-f 9.: a, ;.:Lo,' J,y.a _ _-::5;j "rL ASJL= r.: +iijc \. .:.r. t *;f .i- *:ljf, r,_t? 45.l.; oolc yi 9 o.l.; c:': _-: .-9 r; rlr-i 9r1.:;-l .:9.: Cy- r.: Lo-:"7 cf-.f oclc rlyi j;l SSrr, +;1.:.r:-l if -- - : --* r-,ili-l-* "J".6 jl -raL; o9r-f ,;.l,-toi ;"-l ;l , cf,^* l, Lb,S-L. +iiic.u> +-u r _-&::> ,J _,4 -rJ rlc ;t SxS* *- o*r?s .J|" d ocli'-,"l p;? Jr _p ;J o J"s -t -;*.,r; o.:l.p':...l ";.!i Y Olx. "1 f); : .--.^l Jtl "L rt-t,9 p9c aJj-s.-,L-it ,.-,L,," jl rt: Jt' rL* "5Lop;"-"- 9.,..*-i --- - ;---."--S srslz Jsl-.- ,.iL:!I ,""-*.-,"L;' jl u.u;l Jrt -," 45.\^: a---.f : + --.:-.: -c-b; u-+.):f &L, ,,.-,Lr. + e-t, l& of-f ;ka + .-,I;f.r rrL,J t *. *: _- -e-t" ,5*- ) :-L e-t I (p1)lt 7.f ' O.-r.; e-bl..j*") ,sr-*i *L, C*L, ,,1--).,,1"* ff .rj.u: d"JtL crlg a5 cg;fr* 77 ;\**."1J,J (-*- *ti 9 ?? *> _. .;*..sl.,, ,.o *i_;.Jl :..y.5 rf .s;Ltr;[1 ,l /Y71 o5 *r--.l 611, ,Lr.: )L- YY.J.jJlo ;Lrc q :*L e"t- /ro , ** .--L e-t-*'u* a-t- /Y . l? 9 6* *L- a-t, 7V . l? 9 ;.rl * :f a*t- 7.A/1 -i ,.-rL_rr t 6*1, p.rc.scl.: ;Lr.: a,Y l?) t ry" A ,.: Qp 9 (7\'l.l\ ) ru:-.:|.: oL-,r ! ,s.-; i*U, ,lrL* )3.1 , gl+. ;,: : g_[:;L cu;Lrr "s-F s Jr* rLr.: o9r5 a-_LiL rJ. .r; oo,oLls r-rL-,J dt e-t, f& ( larriyil ,_srLl F jl .Jt $ o.lol; ,._rL_,r a1 *.-J &t, .:r19" ,51 } o:_F Jr p _rr , lrL*:r.;.jlsl a, sly .f lrL;r-r a.5 L* atl q.(p valu:01372) *, o.uLl- os-f * r"-.9r1.:L*"..uU a;lc 64rl.S;/l a.y$ srf ,, ry-|, ;Lrr.;-i +:-;l; ,ji"1il Jr* ;Lrc orl.r,l q .i-;11 ayS trf ,lrk*r ,, lrL*:.-r ,5r^l a-*:.r-rlf ,rLrc + C*L, ,lrL;r.-r ,.5-,j-J1 +y.5:yf,.94"l5 .:,LfAbstract:Background: Vernal keratoconjunctivitis is a bilateral and chronicinflammation of the eye that can lead to severe ocular complications andirnpaired quality of life in the person. Ambernassara is a mildew smoke thathas different rnedical properlies. The purpose of this study is to evaluate theeffect of ambernassara on allergic conjunctivitis disease.Methods: This study is a double blind clinical trial. The statistical populationis all patients who referred to the Ophthalmology Center of Shafa Hospitalin Kerman with the findings of allergic conjunctivitis. The sample w-asselected through available sampling method and 66 subjects were includedin the study. Patients were randomly divided into case and control groups. Inthe case group, the patient was given an ambernassara, and explained thatthey should be exposed to the smoke of the drug for a period of 10 minutesu,hile the dry substance was placed in the spray dish. Then, for a period ofKeep the eyelids closed and rest for a few minutes. In the control group. adrop of fluorometolone is used every 12 hours to use a drop in both e),es.Two drops of optocrorle drops were used to prevent recurrence in both eves.Ophthalmologist's findings and symptoms, and before and after treatmenl.\\'ere completed by the ophthahnologist at the end of the second week an;the end of the llrst month. All patients were advised to avoid direct sunlig;-..and l-reat during this period. ln this study, the response to treatment of patie::sri'as divided into four groups: no response to treatment, a good response r -'.80%o leduction of symptorns), relative response (ie, 40o/o reduction :.svrllptolxs), and appropriate response (ie, response between a good "--:adequate state ) defined. Of the 66 patients enrolled in the study, 34 patie:..received ambernassara,12.5o/o had no response to treatment, and 4.99,0 h:: :good response to treatment, and 53.1% had an appropriate response and l: :.thad appropriate responses to treatment.32 Patients received the usualtreatment, 29% had no response to treatment,5.9o/o had a good response totreatrnent, and 70.60/o had an appropriate response and 20.6% respondedappropliately to treatment.Results: In general, most patients had a relative response to treatment(62.10/o), and only 5 (7 .6%) had no response to treatment. Compared to t1-reusual treatment group and the group treated with ambernassara, in botigroups, in the majority of cases, there was a relative response to treatment.but there was no statistically significant difference between the two groups(p:372.3), meaning that Ambernassara It can be as effective as treatmen:fol allergic conjunctivitis.Conclusion: ambernassara has been effective in treating patients u,i:.allergic conjunctivitis as common as usual.Kel,words: Allergic conjunctivitis, ambernassara, response to treatnte:-,.properlies

کارآزمایی بالینی داروی عنبر نسارا بر بیماران کونژکتیویت آلرژیک مراجعه کننده به درمانگاه چشم بیمارستان شفا در سال ۱۳۹۴

Abstract

Similar works

Full text

Available Versions

Simorgh Research Repository